MedWatch

Smith & Nephew exits tough half year

The British medtech firm has downgraded its full-year expectations after getting off to a bad start in 2022, where Covid-19, a logistics crisis, and inflation have made marks.

Photo: Smith & Nephew / PR

Smith & Nephew has left behind a difficult first half of the year characterized by supply chain issues, which have led to disappointing results for the firm.

Moreover, continued high inflation -- meaning higher costs for the British medtech firm -- and ongoing supply issues have forced Smith & Nephew to downgrade its full-year expectation of an operating margin of ”around 17.5%.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs